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in Finland since 1980 and also slightly from 1990, but real prices
have constantly decreased. Depending from the adjustment index
used, the real prices of all drugs have decreased 35–67% since
1980, or 16–40% since 1990. For reimbursed drugs the devel-
opment was similar; in Basic Refund category real prices have
decreased 24–46% since 1990, and even 45–72% since 1980.
Since the effectiveness of drugs has not decreased during the time
period studied, we suggest that the cost-effectiveness of drug
treatment has clearly increased in Finland.
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OBJECTIVES: To examine resource use and cost of Emergency
Department (ED) and hospital care for acute injuries resulting
from motorcycle accidents. METHODS: 2003 ED visit and hos-
pital discharge data from Massachusetts, where a mandatory all
age helmet law applies, were analyzed. Cases with motorcycle
accident-related injuries were identiﬁed by ICD-9 diagnosis and
external cause codes (E codes: E810.2–E825.2, E810.3–E825.3).
Inpatient cases were restricted to those admitted via ED. Type
and circumstance of injury, time of occurrence, demographics,
costs, length of stay (LOS)/visit, and disposition were examined.
Charges were adjusted by a 0.55 cost-to-charge ratio and
adjusted to national values. Cost estimates (2003US$) include
accommodations and ancillary services. RESULTS: Acute
injuries from motorcycle accidents resulted in 3066 ED visits and
420 hospitalizations during the year. Males comprised 87% of
cases; injured party was driver in 95%. Mean age was 32 years
(49% < 30 years). The majority (76%) occurred between May-
September, Friday-Sunday (52%), and 4:00 PM-midnight (54%).
Multiple injuries were noted in 44% of cases. Head injury/skull
fractures were coded for 8%. Fatalities were noted in <1% of
cases. On average, hospital LOS was 7 days (±10.1) with cost
per stay of $19,535 (±$34,688). At hospital discharge, 82%
went home (14% with home care), 17% transferred to sub-acute
facilities, 1% AMA. ED visit cost without hospitalization was
$787 (±$1,136) and was 2.7 hours (±3), on average. Manage-
ment of these injuries resulted in use of 2877 hospital days and
9274 ED visit hours at a cumulative cost of $10.5 million. CON-
CLUSIONS: This analysis shows that nearly half of the motor-
cycle accident victims sustained more than one injury; the
majority survived, and most acute injuries were managed suc-
cessfully in the ED. Although substantial, these acute care costs
are conservative estimates of injury-related costs, as they do not
include physician-related or post-acute care costs.
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OBJECTIVE: Internal Cost Allocation (ICA), (e.g. Haematol-
ogy—Transfusion medicine), becomes increasingly important,
which is mainly caused by the G-DRG system. To guarantee
optimal patient care, transparency on resources, costs and ben-
eﬁts is necessary. Therefore, in a ﬁrst step resource consumption
in platelet production was assessed to calculate ﬁnally costs from
the provider’s perspective. METHODS: Prospective cost-study
(full cost pricing/process cost ﬁnding). First, main processes of
platelet production were identiﬁed. Secondly, an Excel model for
standardized data entry and calculation was developed. Data
was collected by multimeasurement-time analysis (laboratory
processes three times, other processes ten times) and material
consumption by trained staff. For cost calculations, the deter-
mined average from previous analysis was consulted. Unit cost
data were collected from internal departments, e.g. materials
logistics or personnel management. RESULTS: Platelet produc-
tion consists of ﬁve processes: preparations before and after
donation, medical examination, donation itself and laboratory
tests to detect possible infections and increase blood safety. These
require one secretary, one operator (registered nurse), four
medical-technical-assistants and two doctors. The average of
62.44 minutes per doner could be prorated to the staff as
follows: secretary 8.55%, doctor 7.7%, medical-technical-
assistant 32.63%, and operator 51.12%. At the material con-
sumption, the biggest part belonged to the laboratory reagents,
which are needed for the standard-screening consisting of 
infection-serology, polymerase-chain-reaction, blood-type deter-
mination and the determination of the remaining leucocytes.
Cost evaluation is still ongoing. CONCLUSION: Platelet pro-
duction is a time- and resource-binding process. In the context
of ICA, transparency on costs is important for budget negotia-
tions, particularly when costs and beneﬁts of the introduction of
innovations in transfusion medicine shall be evaluated. It can be
assumed that the relevance of platelet transfusions due to new
therapy approaches is growing and in consequence, product dif-
ferentiation and economic aspects are getting more important for
resource allocation in German hospitals.
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OBJECTIVES: To evaluate user satisfaction from pharmaceuti-
cal care and determine the factors affecting it in Greece.
METHODS: A telephone survey was conducted by using a
random sample of 1000 individuals, stratiﬁed by age, county and
gender. A questionnaire was designed, containing questions
about the characteristics of the drug users, their out of pocket
spending on pharmaceuticals, the type and shape of the drug and
their satisfaction from medication. A logistic regression is done,
using as dependent variables various dimensions of satisfaction,
such as: (a) the drug effectiveness, (b) the drug shape, (c) the
health professionals’ responsiveness, (d) the appearances of side
effects and (e) the price adequacy. As independent variables
various characteristics of the respondents are used such as demo-
graphic, epidemiological and socioeconomic factors. RESULTS:
80% of Greek population is high satisﬁed from pharmaceutical
care, 91.93% from health professionals’ responsiveness, 86.03%
from the non appearances of side effects, 85.59 % from the drug
shape, 62.99 from price adequacy and 59.78% from the drug
effectiveness. Satisfaction from the drug shape, appearance of
side effects, drug effectiveness and improvement of health
depend on health status. Individuals of better health status have
a higher probability to evaluate higher their satisfaction from
medication. Satisfaction from health professionals’ responsive-
ness depends on age. Older individuals have a higher probabil-
ity to evaluate higher their satisfaction from health professionals’
responsiveness. Satisfaction from price adequacy depends on age,
social class and degree of urbanization. Lower social class older
individuals and cities residents have a lower probability to eval-
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uate higher their satisfaction from price adequacy. CONCLU-
SIONS: The evaluation of users’ satisfaction from medication as
well as the determination of the factors affecting it should be
incorporated into the third party payers, the pharmaceutical
industry and the Greek government decision making.
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OBJECTIVE: Many Medicare enrolled veterans view the
Department of Veterans Affairs (VA) as a preferred source of
pharmacy services, even when they have access to pharmacy cov-
erage elsewhere. With the implementation of the Medicare phar-
macy beneﬁt imminent, the objective of these analyses was to
examine how one alternative source of pharmacy care, Medicare
managed care (HMO) enrollment, affects the use of VA phar-
macy services. METHODS: We combined national calendar year
(CY) 2002 Medicare enrollment data for Medicare-enrolled VA
users with pharmacy cost records from the VA’s national Deci-
sion Support System (DSS) ﬁles. VA users were identiﬁed as a
Medicare HMO enrollee if they were enrolled in a Medicare
HMO at any time during CY 2002. RESULTS: In CY 2002, 2.3
million Medicare enrolled veterans (5.4% of all Medicare bene-
ﬁciaries) received medications from the VA, at a total cost of $2.4
billion (68% of all VA pharmacy costs). Across the 127 individ-
ual VA medical centers (VAMCs) there was wide variation in the
percentage of HMO enrollees among Medicare enrolled phar-
macy users (from <1% to >49%) and in the percentage of phar-
macy costs associated with their use (from <1% to >41%). HMO
enrollees were just as likely as non-enrollees to use VA pharmacy
care, although the average annual cost of their care was lower—
$847 per year [sd = $1969] versus $1101 [$2794] for non-
enrollees (p £ 0.0001). CONCLUSIONS: VA users who are
enrolled in Medicare HMOs continue to use VA pharmacy ser-
vices, even though the large majority of them have access to
pharmacy coverage through their HMO plans. Although the
implementation of the Medicare prescription drug beneﬁt in
2006 is expected to increase access to prescription drugs for
Medicare beneﬁciaries, the VA will likely remain a signiﬁcant
pharmacy provider for Medicare enrolled veterans.
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OBJECTIVES: To provide a comprehensive and systematic
review of the literature on medical tourism and health tourism,
to present a grounded conceptual model for the constructs and
to provide a historical background on the matter. METHODS:
“Medical tourism” and “health tourism” were separately
searched using the Medline database to review the literature on
the availability and use of the terms. Given the limited results
for both terms, the broader term “tourism” was searched.
Entries referring to a type of tourism were investigated further
for classiﬁcation of the variants of tourism and to understand
their nature and context of use in the ﬁeld. RESULTS: The
Medline search for “medical tourism” generated only nine
results while the term “health tourism” produced 15 results. The
term “tourism” produced 445 entries 177 of which were non-
English; all languages were considered in the abstract review. Of
the 445 entries, 58 types of tourism and four categories were
generated with “well-being” as main reference for the grounded
conceptual model. Analysis of the results revealed that an explicit
deﬁnition for either term is the exception rather than the rule
and that the two terms are treated as similar concepts. CON-
CLUSION: The review of the literature underlined the problem
of a severely limited literature and the lack of consensus on def-
initions and clarity on the conceptual framework. This paper
deﬁned health tourism as travel outside one’s local environment
for the maintenance, improvement or restoration of the individ-
ual’s well-being in mind and body while medical tourism, a
subset of the health tourism is travel outside one’s natural health
care jurisdiction for the improvement or restoration of the indi-
vidual’s well-being in mind and body. This overview has pre-
sented that as a matter of history, the concept of health tourism
and medical tourism is not new.
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OBJECTIVES: Governmental price regulation of drugs has
become a popular measure to contain health care spending. The
aim is to evaluate the effectiveness of selected demand and supply
side measures, keeping in mind crucial factors in this market, for
instance the free rider problem and moral hazard. METHODS:
To analyze reference price limits on reimbursement a static two
class product model is introduced. Beside this measure addi-
tionally patents, parallel imports as supply side price regulation
and drug budget for physicians and generic drugs as demand side
price regulation will be reviewed. RESULTS: By using a sequen-
tial price-setting process within the model it can be shown that
applying marginal cost pricing for drugs clustered within Phase
1, welfare can be increased. If government sets the reference price
equal to the marginal costs welfare can be increased without free
riding on the sunk R&D costs of researching pharmaceutical
ﬁrms because the patent protection has expired. To give a com-
prehensive evaluation of the other pricing policies the interac-
tions between regulative measures are taken into account.
CONCLUSIONS: In the past too many regulative measures to
contain health care expenditures have been targeted primarily to
supply side measures or to demand side measures. But, regula-
tion that only applies on one side does little to control the rising
expenditures. Without simultaneous use of demand side incen-
tives and volume controls, pharmaceutical expenditures proba-
bly can not be reduced effectively.
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OBJECTIVES: To review the three national bodies responsible
for health technology assessment in the UK: the National Insti-
tute for Health and Clinical Excellence (NICE), the Scottish
Medicines Consortium (SMC) and the All Wales Medicines Strat-
egy Group (AWMSG); to judge their ﬁtness for purpose; and to
assess the value of a multi-layered system. METHODS: The
working of the organisations was classiﬁed under four headings:
objectives and scope; assessment of technologies; the decision
process; implementation. The main source of information was
the documentation produced by these bodies on their rules,
